Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
Go back to Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused| AGIOS PHARM (NASDAQ: AGIO) | Delayed: 35.10 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.10 | 52 Week High | $71.49 | |||
| Open | $35.10 | 52 Week Low | $33.50 | |||
| Day High | $35.10 | P/E | N/A | |||
| Day Low | $35.10 | EPS | $-1.18 | |||
| Volume | 125 | |||||
